[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.163.92.62. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 326
Citations 0
Health Agencies Update
February 26, 2014

Boceprevir Contraindications

JAMA. 2014;311(8):791. doi:10.1001/jama.2014.1337

The hepatitis C medication boceprevir may have harmful interactions with calcium channel blockers and α1-adrenoreceptor antagonists, according to changes to the drug’s label recently approved by the US Food and Drug Administration (FDA).

The FDA approved boceprevir, a protease inhibitor, for the treatment of hepatitis C in May 2011. In April 2012, the agency issued a warning to not prescribe boceprevir in combination with ritonavir-boosted HIV protease inhibitors for individuals coinfected with hepatitis C and HIV because the combination can reduce the effectiveness of the drugs in combating both diseases.

First Page Preview View Large
First page PDF preview
First page PDF preview
×